Aurinia Posts $24.8M Q1 Revenue, Narrows Loss to $0.20/Share with $342M Cash
Aurinia Pharmaceuticals reported Q1 revenue of $24.8 million, driven by Lupkynis sales, reducing its net loss to $18.9 million (-$0.20/share) compared with a $22.3 million loss in Q1 2025. The company held $342 million cash at quarter-end, launched a pediatric Phase III nephritis trial and filed for EU approval.
1. Q1 Financial Results
Aurinia recorded revenue of $24.8 million for the three months ended March 31, 2026, up 62% year-over-year, primarily from U.S. Lupkynis product sales. The company reported a net loss of $18.9 million, or $0.20 per share, improved from a $22.3 million, $0.25 per share loss in Q1 2025.
2. Cash Position and Runway
Cash, cash equivalents and marketable securities totaled $342 million at quarter-end, up from $330 million at year-end 2025, providing runway into late 2028. Operating expenditures in Q1 declined by 8% versus the prior quarter following cost-efficiency measures.
3. Pipeline and Regulatory Updates
Aurinia initiated a global Phase III trial evaluating Lupkynis in pediatric lupus nephritis in April and expects topline data in early 2028. The company also submitted a Marketing Authorization Application for lupus nephritis in the European Union, targeting a decision by mid-2027.
4. Strategic Initiatives and Outlook
Management plans to expand EU commercial infrastructure ahead of potential approval, while continuing enrollment in the ongoing Phase II lupus rash study. Full-year 2026 guidance will be provided at the upcoming investor conference in June.